Immuneering’s (IMRX) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research note released on Tuesday,Benzinga reports. Needham & Company LLC currently has a $15.00 target price on the stock.

Several other research analysts also recently commented on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $13.00 price target on shares of Immuneering in a research note on Wednesday, November 20th. Morgan Stanley lowered shares of Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $12.80.

Immuneering Stock Down 15.3 %

Shares of Immuneering stock opened at $2.00 on Tuesday. Immuneering has a 52 week low of $1.00 and a 52 week high of $7.68. The company has a market capitalization of $62.10 million, a PE ratio of -1.02 and a beta of -0.34. The stock’s fifty day moving average is $2.04 and its two-hundred day moving average is $1.77.

Institutional Investors Weigh In On Immuneering

Large investors have recently modified their holdings of the business. Marshall Wace LLP purchased a new position in Immuneering during the second quarter valued at approximately $492,000. Renaissance Technologies LLC purchased a new stake in Immuneering during the 2nd quarter worth approximately $447,000. HighTower Advisors LLC grew its position in Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock worth $132,000 after purchasing an additional 9,400 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Immuneering during the 2nd quarter valued at approximately $67,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Immuneering during the second quarter worth $44,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.